Download Sample
Add to CartGlobal C-Reactive Protein (CRP) Test Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Assay Type;
Immunoturbidimetric Assay and Enzyme-Linked Immunosorbent Assay (ELISA) - Clinical & Non-Clinical, Chemiluminescence Immunoassay (CLIA), and Others.By Detection Range;
High Sensitivity C-reactive Protein, Conventional CRP, and Cardiac CRP (cCRP).By Disease Area;
Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, and Others.By End Use;
Clinics, Hospitals, Laboratories, Assisted Living Healthcare Facilities, Home, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global C-Reactive Protein (CRP) Test Market (USD Million), 2021 - 2031
In the year 2024, the Global C-Reactive Protein (CRP) Test Market was valued at USD 3,114.62 million. The size of this market is expected to increase to USD 4,261.33 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.6%.
The global C-Reactive Protein (CRP) test market has witnessed significant expansion driven by various factors influencing the demand and adoption of CRP testing across healthcare settings worldwide. C-Reactive Protein, an acute-phase protein produced by the liver in response to inflammation, infection, or tissue injury, serves as a crucial biomarker for assessing inflammation levels in the body.
One of the primary growth drivers for the CRP test market is the rising prevalence of chronic inflammatory diseases such as cardiovascular diseases, rheumatoid arthritis, and inflammatory bowel diseases. These conditions necessitate regular monitoring of CRP levels to assess disease activity and guide treatment decisions effectively.
Furthermore, technological advancements in CRP testing methods have played a pivotal role in market expansion. Innovations such as high-sensitivity CRP assays have improved the accuracy and reliability of CRP measurements, thereby enhancing their clinical utility. This has contributed to the wider adoption of CRP testing not only in hospitals but also in diagnostic laboratories and outpatient clinics.
The increasing awareness among healthcare professionals about the prognostic value of CRP testing in predicting cardiovascular events and guiding therapeutic interventions has also bolstered market growth. CRP levels are used not only as diagnostic markers but also as indicators of disease severity and response to treatment, thus fostering their integration into routine clinical practice.
Geographically, North America and Europe have traditionally held significant market shares due to their well-established healthcare infrastructure and early adoption of advanced diagnostic technologies. However, emerging economies in Asia Pacific and Latin America are also witnessing rapid market growth, driven by improving healthcare infrastructure, increasing healthcare expenditure, and growing awareness about preventive healthcare measures.
The global CRP test market is poised for continued growth, driven by the increasing burden of chronic diseases, technological advancements in testing methods, and expanding healthcare access in developing regions. As research continues to elucidate the role of CRP in various disease states, the market is expected to witness further expansion with enhanced diagnostic capabilities and broader clinical applications.
Global C-Reactive Protein (CRP) Test Market Recent Developments
-
In January 2022, LumiraDx obtained C.E. mark clearance for its C-reactive protein PCR test. This microfluidic immunoassay is designed for the quantitative detection of C-reactive protein. It's compact, portable, and delivers results in just four minutes.
-
In August 2021, Immunovia, Inc. announced that it received final approval to begin patient testing for the IMMray PanCan-d test, designed specifically for the early detection of pancreatic cancer.
Segment Analysis
C-reactive protein (CRP) assays are widely utilized in both clinical and non-clinical applications to evaluate inflammation levels in the body. Commonly employed assay types include Immunoturbidimetric Assay, Enzyme-Linked Immunosorbent Assay (ELISA), and Chemiluminescence Immunoassay (CLIA), among others. Each assay offers distinct advantages in terms of sensitivity, specificity, and ease of use, with Immunoturbidimetric and ELISA often preferred in clinical settings due to their established protocols, while CLIA is known for its enhanced sensitivity and is valuable in scenarios where precise quantification is essential.
These assays cover various detection ranges tailored to specific diagnostic needs: high-sensitivity CRP, conventional CRP, and cardiac CRP (cCRP). High-sensitivity CRP assays are frequently used for cardiovascular disease risk assessment, as they detect low levels of CRP associated with chronic inflammation. Conventional CRP assays are commonly applied to general inflammatory conditions, while cardiac CRP provides more precise information on cardiac-related inflammation, aiding in identifying patients at risk of cardiovascular events. Together, these detection ranges allow for a tailored approach to CRP measurement, meeting specific patient and disease requirements.
CRP testing is essential across diverse disease areas, including cardiovascular diseases, cancer, rheumatoid arthritis, inflammatory bowel disease, endometriosis, and lupus. Given their relevance, these assays are implemented across a variety of healthcare settings, including hospitals, clinics, laboratories, assisted living healthcare facilities, and even home settings for remote or continuous monitoring. The versatility of CRP assays in end-use settings underscores their value in personalized patient care, enabling healthcare professionals to diagnose, monitor, and manage various chronic and acute inflammatory conditions effectively.
Global C-Reactive Protein (CRP) Test Segment Analysis
In this report, the Global C-Reactive Protein (CRP) Test Market has been segmented by Assay Type, Detection Range, Disease Area, End Use and Geography.
Global C-Reactive Protein (CRP) Test Market, Segmentation by Assay Type
The Global C-Reactive Protein (CRP) Test Market has been segmented by Assay Type into Immunoturbidimetric Assay, Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA) and Others.
Immunoturbidimetric assays, known for their high sensitivity and specificity, dominate the market due to their wide adoption in routine diagnostic procedures. These assays utilize antibodies that bind specifically to CRP molecules, causing a measurable change in turbidity which correlates with CRP concentration. This method's efficiency in quantifying CRP levels swiftly and accurately has made it a preferred choice in laboratories and healthcare facilities worldwide.
Enzyme-Linked Immunosorbent Assay (ELISA) assays also play a significant role in the market, offering precise quantification of CRP through the enzymatic reaction between CRP and specific antibodies. ELISA assays are valued for their versatility and ability to detect low levels of CRP, making them essential in research settings and clinical diagnostics requiring high sensitivity.
Chemiluminescence Immunoassays (CLIA) have gained traction for their enhanced sensitivity and automation capabilities, allowing for rapid and precise measurement of CRP levels in various biological samples. These assays use chemiluminescent reactions to quantify CRP, offering advantages in terms of speed, reproducibility, and throughput, which are crucial in high-volume diagnostic settings.
Other assay types in the CRP test market include molecular diagnostics and point-of-care testing methods, which are increasingly being developed to provide rapid results at the bedside or in remote settings. These innovations aim to improve patient care by enabling prompt decision-making based on CRP levels, particularly in emergency and critical care scenarios.
Global C-Reactive Protein (CRP) Test Market, Segmentation by Detection Range
The Global C-Reactive Protein (CRP) Test Market has been segmented by Detection Range into High sensitivity C-reactive protein, Conventional CRP and Cardiac CRP (cCRP).
High sensitivity C-reactive protein (hs-CRP) assays are designed to detect extremely low levels of CRP in the blood, often in the range of 0.1 to 10 mg/L. These assays are crucial for assessing low-grade inflammation associated with chronic conditions such as cardiovascular disease, where even minor elevations in CRP levels can indicate increased risk.
Conventional CRP assays, on the other hand, typically detect CRP levels in the range of 10 to 1000 mg/L. They are widely used in routine clinical settings to monitor acute inflammation and infection, providing quick results that aid in diagnosing conditions such as bacterial infections and inflammatory disorders.
Cardiac CRP (cCRP) tests specifically measure CRP levels associated with cardiovascular risk, focusing on detecting inflammation related to heart disease. This segment targets a narrower range of CRP concentrations relevant to assessing cardiac health and predicting cardiovascular events.
Global C-Reactive Protein (CRP) Test Market, Segmentation by Disease Area
The Global C-Reactive Protein (CRP) Test Market has been segmented by Disease Area into Cardiovascular diseases, Cancer, Rheumatoid Arthritis, Inflammatory bowel disease, Endometriosis, Lupus and Others.
Cardiovascular diseases constitute a significant segment, where CRP testing is pivotal for assessing inflammation levels linked to heart conditions and predicting cardiovascular risk. Elevated CRP levels often indicate underlying inflammation associated with atherosclerosis and other cardiovascular disorders, guiding treatment strategies and monitoring disease progression.
Cancer represents another critical segment in the CRP test market, as CRP levels can serve as biomarkers for inflammatory responses in cancer patients. Monitoring CRP helps oncologists evaluate treatment responses, detect cancer-related inflammation, and assess overall prognosis. The use of CRP testing in cancer management underscores its role in personalized medicine and enhancing patient care outcomes.
Additionally, CRP testing finds application in autoimmune diseases such as rheumatoid arthritis, lupus, and inflammatory bowel disease. These conditions involve chronic inflammation, where CRP levels serve as indicators of disease activity and response to therapy. In clinical practice, CRP tests aid in diagnosing flare-ups, monitoring disease progression, and adjusting treatment regimens to improve patient outcomes.
Global C-Reactive Protein (CRP) Test Market, Segmentation by End Use
The Global C-Reactive Protein (CRP) Test Market has been segmented by End Use into Clinics, Hospitals, Laboratories, Assisted living healthcare facilities, Home and Others.
Hospitals represent a major end-use segment, where CRP tests are routinely conducted in emergency departments, inpatient wards, and outpatient clinics. Hospitals require rapid and accurate CRP results to aid in diagnosing acute infections, assessing disease severity, and guiding treatment decisions across a wide range of medical specialties.
Laboratories also play a crucial role in the CRP test market, serving as central hubs for conducting diagnostic tests and processing patient samples. These facilities utilize advanced assay methods to measure CRP levels with precision, supporting healthcare providers in diagnosing inflammatory diseases and monitoring patient responses to therapy. Laboratories often collaborate with hospitals and clinics to deliver timely test results and ensure comprehensive patient care.
Clinics and assisted living healthcare facilities constitute another significant segment in the CRP test market, catering to outpatient care and long-term management of chronic conditions. CRP testing in these settings helps primary care physicians and specialists monitor inflammation levels, track disease progression, and optimize treatment plans tailored to individual patient needs.
Global C-Reactive Protein (CRP) Test Market, Segmentation by Geography
In this report, the Global C-Reactive Protein (CRP) Test Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global C-Reactive Protein (CRP) Test Market Share (%), by Geographical Region, 2024
North America and Europe represent mature markets with established healthcare infrastructures and high adoption rates of advanced diagnostic technologies. These regions lead in CRP testing due to their focus on preventive healthcare measures, early disease detection, and robust research and development activities. The presence of key market players, coupled with supportive regulatory frameworks, further drives market growth in these regions.
The Asia Pacific region is experiencing rapid market expansion, propelled by increasing healthcare expenditure, rising prevalence of chronic diseases, and growing awareness about the importance of early disease diagnosis. Countries like China, India, and Japan are witnessing significant investments in healthcare infrastructure and technological advancements, fostering the adoption of CRP testing for effective disease management and improving patient outcomes. The Middle East and Africa, along with Latin America, are emerging markets for CRP tests, characterized by improving healthcare access and infrastructure development. These regions are witnessing a gradual shift towards preventive healthcare practices and diagnostic advancements, which are expected to drive the demand for CRP testing in the coming years.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global C-Reactive Protein (CRP) Test Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunities
Drivers
- Increasing Incidence of Chronic Diseases
- Advancements in High-Sensitivity CRP Testing
-
Growing Aging Population: The global demographic shift towards an aging population is significantly impacting healthcare systems worldwide. As people age, they become more susceptible to chronic illnesses such as cardiovascular diseases, arthritis, diabetes, and certain cancers. These conditions often involve inflammation as a critical component of their pathophysiology. C-Reactive Protein (CRP) is a biomarker that reflects systemic inflammation levels in the body. Elevated CRP levels are commonly associated with these chronic conditions and can serve as an important indicator for disease severity and progression.
With the aging population experiencing higher incidences of chronic illnesses, there is a growing demand for diagnostic tools like CRP tests that can aid in early detection, monitoring, and management of these diseases. Healthcare providers rely on CRP testing to assess inflammatory status, guide treatment decisions, and evaluate the effectiveness of therapeutic interventions. Moreover, CRP tests are instrumental in identifying individuals at higher risk for cardiovascular events, enabling proactive interventions to mitigate risks and improve patient outcomes.
Restraints
- High Cost of CRP Testing
- Regulatory Challenges
-
Limited Awareness and Access in Developing Regions: In many developing regions around the world, lack of awareness about the importance of CRP testing poses a significant barrier to market growth. Public knowledge regarding the role of CRP as a biomarker for inflammation and its implications in diagnosing and managing chronic diseases is often limited. This lack of awareness extends to healthcare providers and policymakers, who may not prioritize CRP testing as a routine diagnostic tool due to competing healthcare priorities and resource constraints.
Limited access to healthcare facilities exacerbates the challenge. Rural areas and underserved urban communities in developing regions often face infrastructural deficiencies, including inadequate laboratory facilities and diagnostic equipment. This shortage not only restricts the availability of CRP testing but also impedes timely access to healthcare services for populations in need. Without access to reliable diagnostic testing, individuals may experience delays in disease diagnosis, suboptimal management of chronic conditions, and increased healthcare disparities.
Opportunities
- Expansion of Point-of-Care Testing (POCT)
- Integration with Personalized Medicine
-
Emerging Markets and Technological Innovations: Expanding market presence in emerging economies presents significant opportunities for CRP testing providers. As healthcare infrastructure improves in these regions, there is a growing demand for diagnostic tools that can aid in the early detection and management of chronic diseases. Governments and private healthcare providers in emerging economies are increasingly investing in healthcare facilities, diagnostic laboratories, and medical equipment, creating a conducive environment for the adoption of advanced CRP testing technologies. This expansion not only addresses the healthcare needs of a larger patient population but also opens up new market segments for CRP testing companies looking to establish a foothold in these rapidly developing regions.
Ongoing technological innovations in CRP testing methodologies and platforms are driving market growth by enhancing test accuracy, efficiency, and usability. Advances in assay sensitivity, automation, and integration with point-of-care devices are streamlining the CRP testing process, reducing turnaround times, and improving diagnostic reliability. These innovations are particularly beneficial in diverse healthcare settings, including hospitals, clinics, and community health centers, where rapid and precise CRP test results are essential for informed clinical decision-making. By leveraging these technological advancements, CRP testing providers can not only meet current market demands but also differentiate themselves through superior product performance and user-friendly interfaces, thereby expanding their market share globally.
Competitive Landscape Analysis
Key players in Global C-Reactive Protein (CRP) Test Market include
- Thermo Fisher Scientific, Inc.
- Ortho Clinical Diagnostics
- F Hoffmann-La Roche Ltd.
- Danaher
- Quest Diagnostics
- Siemens Healthineers
- Abbott
- Abaxis, Inc.
- Merck & Co., Inc.
- LabCorp
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Assay Type
- Market Snapshot, By Detection Range
- Market Snapshot, By Disease Area
- Market Snapshot, By End Use
- Market Snapshot, By Region
- Global C-Reactive Protein (CRP) Test Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Incidence of Chronic Diseases
- Advancements in High-Sensitivity CRP Testing
- Growing Aging Population
- Restraints
- High Cost of CRP Testing
- Regulatory Challenges
- Limited Awareness and Access in Developing Regions
- Opportunities
- Expansion of Point-of-Care Testing (POCT)
- Integration with Personalized Medicine
- Emerging Markets and Technological Innovations
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global C-Reactive Protein (CRP) Test Market, By Assay Type, 2021 - 2031 (USD Million)
- Immunoturbidimetric Assay
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Clinical
- Non-Clinical
- Chemiluminescence Immunoassay (CLIA)
- Others
- Global C-Reactive Protein (CRP) Test Market, By Detection Range, 2021 - 2031 (USD Million)
- High sensitivity C-reactive protein
- Conventional CRP
- Cardiac CRP (cCRP)
- Global C-Reactive Protein (CRP) Test Market, By Disease Area, 2021 - 2031 (USD Million)
- Cardiovascular diseases
- Cancer
- Rheumatoid Arthritis
- Inflammatory bowel disease
- Endometriosis
- Lupus
- Others
- Global C-Reactive Protein (CRP) Test Market, By End Use, 2021 - 2031 (USD Million)
- Clinics
- Hospitals
- Laboratories
- Assisted living healthcare facilities
- Home
- Others
- Global C-Reactive Protein (CRP) Test Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global C-Reactive Protein (CRP) Test Market, By Assay Type, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Thermo Fisher Scientific, Inc.
- Ortho Clinical Diagnostics
- F Hoffmann-La Roche Ltd.
- Danaher
- Quest Diagnostics
- Siemens Healthineers
- Abbott
- Abaxis, Inc.
- Merck & Co., Inc.
- LabCorp
- Company Profiles
- Analyst Views
- Future Outlook of the Market